Anne E. Deconinck

Anne E. Deconinck has a diverse work experience spanning over 30 years. Anne E. is currently employed at Dragonfly Therapeutics, Inc. where they hold the position of Executive Director of Corporate Development since May 2022. Prior to this role, Anne held the positions of Senior Director of Corporate Development and Director of Corporate Development at the same company from 2019 to 2022. Before joining Dragonfly Therapeutics, Anne worked at Skyhawk Therapeutics as a Senior Director of Corporate Development and as a Director of Corporate Development from 2019 to 2021.

Anne's earlier work experience includes a significant tenure at the Massachusetts Institute of Technology (MIT). Anne E. served as the Executive Director of the Koch Institute for Integrative Cancer Research from 2013 to 2019. In this role, they played a pivotal role in advancing interdisciplinary cancer research and developing new tools and technologies for cancer detection and treatment. Prior to this, Anne served as the Assistant Director for Research Development and Outreach at MIT from 2012 to 2013, where they helped establish collaborations and fostered research partnerships. Anne E. also worked as the Collaborative Programs Manager, overseeing a strategic partnership with Janssen Pharmaceuticals from 2011 to 2012. Additionally, Anne worked as a Research Specialist and played a crucial role in the establishment of the Koch Institute at MIT in 2007.

Anne's earliest work experience can be traced back to their internship at Celltech in 1990-1991.

Anne E. Deconinck began their education at the European School Brussels, where they earned a European Baccalaureate. Anne E. then pursued their undergraduate studies at King's College London, where they obtained a B.Sc. in Biochemistry from 1988 to 1992. Following this, they furthered their education at the University of Oxford, obtaining a Ph.D. in Biological Sciences from 1992 to 1996. Anne E. Deconinck later pursued a postdoctoral position at Harvard University, specifically at the Harvard Medical School, specializing in Hematology/Oncology from 1997 to 2000.